Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03241745
Other study ID # 17-180
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date August 3, 2017
Est. completion date April 1, 2024

Study information

Verified date April 2024
Source Memorial Sloan Kettering Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to test the safety of nivolumab and find out what affects, if any, nivolumab has on people and their risk of gynecologic cancer. The investigators also want to find out what effects, good or bad, nivolumab has on the patient and their cancer.


Recruitment information / eligibility

Status Completed
Enrollment 35
Est. completion date April 1, 2024
Est. primary completion date April 1, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically confirmed diagnosis of metastatic or recurrent uterine cancer (endometrial carcinoma, carcinosarcoma, clear cell carcinoma, leiomyosarcoma, undifferentiated sarcoma, high grade endometrial stromal sarcoma) by Memorial Sloan Kettering Cancer Center. Carcinosarcomas, endometrioid and clear cell carcinomas that appears to have arisen in the ovary/fallopian tube or peritoneum are also eligible. Recurrence should not be amenable to curative approaches such as surgical resection or chemoradiotherapy. - Tumor is confirmed to be one of the following: 1. MSI-high, or 2. MMR-deficient, or 3. Hypermutated defined as =20 somatic mutations in the tumor by MSK-IMPACT - One or more prior lines of cytotoxic treatment for advanced disease (prior hormonal therapy is not considered to count as prior lines of therapy) - Measurable disease by RECIST 1.1 criteria - No known CNS metastases - ECOG Performance status 0-1 - ECOG Performance status 0-1 - WBC = 2000/uL, ANC = 1500/uL, PLT = 100,000/uL, HGB = 8 g/dL - Serum creatinine = 1.5 x ULN or creatinine clearance of = 40mL/min by Cockroft-Gault formula - AST (SGOT) and ALT (SGPT) = 3 x ULN - Total bilirubin = 1.5 x ULN, except subjects with Gilbert's syndrome who can have total bilirubin = 3.0 mg/dL - Able to sign voluntary written informed consent - Female, 18 years of age or older - Available archival tumor tissue or patient is willing to undergo new biopsy - Premenopausal women of child bearing potential must have a normal urine or serum beta-HCG prior to enrollment, and must agree to use effective contraception during treatment with nivolumab and for at least 5 months following the last dose of nivolumab. Exclusion Criteria: - Disease eligible for potentially curative treatment with standard chemotherapy, surgical resection, or chemoradiotherapy. - Known or suspected autoimmune disease, except for subjects with vitiligo, diabetes mellitus, resolved childhood asthma/atopy, residual hypothyroidism due to an autoimmune immune condition only requiring thyroid hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger. - Serious uncontrolled medical disorder or active infection which would impair the ability of the subject to receive protocol therapy or whose control would be jeopardized by protocol therapy - History of bowel obstruction, refractory ascites, or bowel perforation due to advanced disease within the past 3 months from start of study treatment. - Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T cell co-stimulation or immune checkpoint pathways - Patients who have a condition that requires systemic treatment with either corticosteroids within 7 days of enrollment (systemic corticosteroid therapy is defined as >10 mg daily prednisone or its equivalent); or who require other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. - Prior history of malignancy or a concurrent malignancy, with the exception of cutaneous basal cell carcinoma or squamous cell carcinoma, superficial bladder cancer, or in situ carcinoma of the uterine cervix, prostate, or breast, unless a complete remission was achieved at least 3 years prior to study entry and no additional therapy is required or anticipated to be required during the study period - Breastfeeding women, pregnant women - Prisoners or subjects who are involuntarily incarcerated - Subjects who are compulsorily detained for treatment of either a psychiatric or physical illness - Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection (if patient has documented Hepatitis B and C from within 6 months of enrollment, these tests do not need to be repeated.) - Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) - Known allergy or Adverse Drug Reaction to nivolumab, or a history of allergy to study drug components.

Study Design


Intervention

Drug:
Nivolumab
Nivolumab 480 mg IV once every 4 weeks

Locations

Country Name City State
United States Lehigh Valley Health Network Allentown Pennsylvania
United States Memorial Sloan Kettering Basking Ridge Basking Ridge New Jersey
United States Memorial Sloan Kettering Commack Commack New York
United States Memorial Sloan Kettering Westchester Harrison New York
United States Memorial Sloan Kettering Monmouth Middletown New Jersey
United States Memorial Sloan Kettering Bergen Montvale New Jersey
United States Memorial Sloan Kettering Cancer Center New York New York
United States Memorial Sloan Kettering Nassau Uniondale New York

Sponsors (2)

Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center Bristol-Myers Squibb

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-Free Survival will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) at 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT03285802 - Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Phase 2/Phase 3
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Not yet recruiting NCT05998811 - Insights Into Participating in Studies for Uterine Cancer
Not yet recruiting NCT06369155 - Azenosertib in Uterine Serous Carcinoma: Biomarker Study Phase 2
Completed NCT01432015 - Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting Phase 4
Completed NCT01399658 - Image-Guided Gynecologic Brachytherapy Phase 2
Recruiting NCT02349958 - Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy Phase 2
Completed NCT00581646 - Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance N/A
Completed NCT00284427 - Safety of Antioxidants During GYN Cancer Care Phase 2
Completed NCT00147680 - Uterine Papillary Serous Cancer (UPSC) Trial Phase 2
Recruiting NCT05743517 - Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment) N/A
Recruiting NCT05916196 - [18F]FES PET/.CT in Uterine Cancer Phase 2
Withdrawn NCT04368130 - SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care N/A
Active, not recruiting NCT03668340 - AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma Phase 2
Completed NCT00588640 - Study of D-Methadone in Patients With Chronic Pain Phase 1/Phase 2
Recruiting NCT05990426 - Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy N/A
Completed NCT03701529 - Effect of Anesthetic Agents on Optic Nerve Sheath Diameter N/A
Recruiting NCT05758688 - Whole Pelvis Proton Radiation for Gynecologic Cancer N/A
Completed NCT01953107 - Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. Phase 4